BR0210550A - Método para realçar a eficácia de terapias contra o câncer - Google Patents

Método para realçar a eficácia de terapias contra o câncer

Info

Publication number
BR0210550A
BR0210550A BR0210550-0A BR0210550A BR0210550A BR 0210550 A BR0210550 A BR 0210550A BR 0210550 A BR0210550 A BR 0210550A BR 0210550 A BR0210550 A BR 0210550A
Authority
BR
Brazil
Prior art keywords
effectiveness
cancer therapies
enhance
therapeutic material
galectins
Prior art date
Application number
BR0210550-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Yang Chang
Vodek Sasek
Original Assignee
Glycogenesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycogenesys Inc filed Critical Glycogenesys Inc
Publication of BR0210550A publication Critical patent/BR0210550A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/732—Pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
BR0210550-0A 2001-06-21 2002-06-21 Método para realçar a eficácia de terapias contra o câncer BR0210550A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29999101P 2001-06-21 2001-06-21
US10/176,235 US6680306B2 (en) 2001-06-21 2002-06-20 Method for enhancing the effectiveness of cancer therapies
PCT/US2002/019885 WO2003000118A2 (en) 2001-06-21 2002-06-21 Method for enhancing the effectiveness of cancer therapies

Publications (1)

Publication Number Publication Date
BR0210550A true BR0210550A (pt) 2004-05-25

Family

ID=26872020

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0210550-0A BR0210550A (pt) 2001-06-21 2002-06-21 Método para realçar a eficácia de terapias contra o câncer

Country Status (11)

Country Link
US (3) US6680306B2 (enExample)
EP (1) EP1406639A4 (enExample)
JP (1) JP2004535430A (enExample)
CN (1) CN100558367C (enExample)
AU (1) AU2002320140B2 (enExample)
BR (1) BR0210550A (enExample)
CA (1) CA2451841A1 (enExample)
CZ (1) CZ200487A3 (enExample)
IL (1) IL159461A0 (enExample)
MX (1) MXPA03012021A (enExample)
WO (1) WO2003000118A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2440555A1 (en) * 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
US6680306B2 (en) * 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
US20030004132A1 (en) * 2001-06-22 2003-01-02 Yan Chang Method and material for treating immune diseases
US6890906B2 (en) 2001-11-21 2005-05-10 Glycogenesys, Inc. Method for controlling angiogenesis in animals
US20040121981A1 (en) * 2001-11-21 2004-06-24 Glycogenesys, Inc. Method for controlling angiogenesis in animals
US20040259816A1 (en) * 2002-10-01 2004-12-23 Pandol Stephen J. Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof
AU2004229399B2 (en) * 2003-04-07 2010-08-05 Prospect Therapeutics, Inc. Composition and uses of galectin antagonists
US20040223971A1 (en) * 2003-04-07 2004-11-11 Glycogenesys, Inc. Composition and uses of galectin antagonists
WO2005007110A2 (en) * 2003-07-11 2005-01-27 Pro-Pharmaceuticals, Inc. Compositions and methods for hydrophobic drug delivery
DE10335236B3 (de) * 2003-08-01 2005-02-24 Drägerwerk AG Messsystem für die Bestimmung der Konzentration von Propofol (2,6-Diisopropylphenol) im Atemstrom
US20050053664A1 (en) 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
EP2591786B1 (en) 2003-10-16 2017-04-12 Cancure Limited Immunomodulating compositions and uses therefor
US20050282773A1 (en) * 2004-01-14 2005-12-22 Pro-Pharmaceuticals, Inc. Modified polysaccharides in combination with anti-cancer drugs for enhanced treatment of cancer
EP1718146A2 (en) * 2004-02-13 2006-11-08 Pro-Pharmaceuticals, Inc. Compositions and methods used to treat acne and candida
CA2582428A1 (en) 2004-03-26 2005-10-13 Glycogenesys, Inc. Modified pectins, compositions and methods related thereto
WO2006020027A1 (en) * 2004-07-14 2006-02-23 Glycogenesys, Inc. Composition and method for treating hyperproliferative diseases
EP1773128A2 (en) * 2004-08-02 2007-04-18 Pro-Pharmaceuticals, Inc. Compositions and methods for the enhancement of chemotherapy with microbial cytotoxins
BRPI0607579A2 (pt) * 2005-03-23 2009-09-15 Pfizer Prod Inc uso de anticorpo anti-ctla4 e indolinona para a preparação de medicamentos para o tratamento de cáncer
US8221803B1 (en) 2007-06-25 2012-07-17 OncoNatural Solutions, Inc. Composition for prostate health
US7919250B2 (en) * 2007-07-31 2011-04-05 New York University Diagnostic and treatment methods for characterizing bacterial microbiota in skin conditions
CA2778953C (en) 2009-11-13 2020-01-14 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
EP2788761B1 (en) * 2011-12-08 2018-02-28 Eliaz Therapeutics, Inc. Reduction of galectin-3 levels by plasmapheresis
KR101968370B1 (ko) * 2011-12-28 2019-04-11 갈렉틴 테라퓨틱스, 인크. 인간 질환의 치료를 위한 신규 탄수화물 약물의 조성물
WO2013152313A1 (en) * 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
ES2848538T3 (es) 2012-06-06 2021-08-10 Galectin Therapeutics Inc Composiciones de galacto-ramnogalacturonato para el tratamiento de enfermedades asociadas con elevada óxido nítrico sintasa inducible
BR112015005772A2 (pt) 2012-09-17 2017-08-08 Galectin Therapeutics Inc método para a intensificação de imunoterapias específicas no tratamento de câncer
JP6055928B2 (ja) 2012-10-10 2016-12-27 ガレクティン・セラピューティクス・インコーポレイテッドＧａｌｅｃｔｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 糖尿病性腎症および関連障害の処置のためのガラクトース分枝炭水化物化合物
US9339515B2 (en) 2013-02-20 2016-05-17 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis
CA2930817A1 (en) 2013-11-17 2015-05-21 Rdd Pharma Ltd. Methods for treating radiation induced gastrointestinal tract injury
CA3031691A1 (en) * 2016-09-13 2018-03-22 Rasna Research Inc. Dactinomycin compositions and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
CA3062648A1 (en) 2017-05-12 2018-11-15 Galectin Sciences, Llc Compounds for the prevention and treatment of diseases and the use thereof
US11633399B2 (en) 2018-12-25 2023-04-25 Sol-Gel Technologies Ltd. Treatment of skin disorders with compositions comprising an EGFR inhibitor

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US107222A (en) * 1870-09-13 Improvement in machines for tenoning window-sash
US5490991A (en) 1986-07-03 1996-02-13 Advanced Magnetics, Inc. Directed delivery of radioprotectants using a receptor specific carrier
US5843442A (en) 1990-10-22 1998-12-01 Corvas International, Inc. Blood coagulation protein antagonists and uses therefor
US5639737A (en) 1991-11-04 1997-06-17 Co Enzyme Technology Ltd. Method and compositions for treating malignant tumors and inhibiting growth and metastases of malignant tumors
US20020107222A1 (en) 1993-03-01 2002-08-08 David Platt Modified polysaccharides for treatment of cancer
US5490911A (en) * 1993-11-26 1996-02-13 The United States Of America As Represented By The Department Of Energy Reactive multilayer synthesis of hard ceramic foils and films
US5498702A (en) * 1993-12-16 1996-03-12 California Natural Products Treated pectinic acid process and product
US5834442A (en) * 1994-07-07 1998-11-10 Barbara Ann Karmanos Cancer Institute Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin
US5681923A (en) 1995-10-06 1997-10-28 Platt; David Tumor derived carbohydrate binding protein
KR19990087665A (ko) * 1996-03-15 1999-12-27 오미야 히사시 우론산의 가열-처리 산물, 이를 함유하는 식품, 음료 또는 약제
US5831052A (en) * 1997-05-07 1998-11-03 Incyte Pharmaceuticals, Inc. New human translocation associated protein
EP1391206B1 (en) * 1997-10-15 2008-07-02 Polarx Biopharmaceuticals, Inc. Pharmaceutical compositions comprising arsenic trioxide for the treatment of non-Hodgkin's lymphoma
US6258383B1 (en) * 1998-08-14 2001-07-10 Lactoferrin Products Company Dietary supplement combining colostrum and lactoferrin in a mucosal delivery format
US6500807B1 (en) * 1999-02-02 2002-12-31 Safescience, Inc. Modified pectin and nucleic acid composition
US6274566B1 (en) * 1999-02-23 2001-08-14 Econugenics, Inc. Methods for treating mammals with modified alginates and pectins
WO2002026262A2 (en) 2000-09-25 2002-04-04 Pro-Pharmaceuticals, Inc. Compositions for reducing side effects in chemotherapeutic treatments
US20020104222A1 (en) * 2001-02-06 2002-08-08 Jay Larry Dean Knife for removing the hide of an animal and method therefor
US6914055B2 (en) * 2001-03-27 2005-07-05 Anatole Klyosov Delivery of a therapeutic agent in a formulation for reduced toxicity
US6645946B1 (en) * 2001-03-27 2003-11-11 Pro-Pharmaceuticals, Inc. Delivery of a therapeutic agent in a formulation for reduced toxicity
US6982255B2 (en) * 2001-03-27 2006-01-03 Anatole Klyosov Delivery of a therapeutic agent in a formulation for reduced toxicity
WO2002076474A1 (en) 2001-03-27 2002-10-03 Pro-Pharmaceuticals, Inc. Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
US6680306B2 (en) * 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
US20040223971A1 (en) * 2003-04-07 2004-11-11 Glycogenesys, Inc. Composition and uses of galectin antagonists
WO2006020027A1 (en) * 2004-07-14 2006-02-23 Glycogenesys, Inc. Composition and method for treating hyperproliferative diseases

Also Published As

Publication number Publication date
MXPA03012021A (es) 2004-06-03
EP1406639A4 (en) 2004-07-28
US6680306B2 (en) 2004-01-20
AU2002320140B2 (en) 2007-11-29
EP1406639A2 (en) 2004-04-14
US20040043962A1 (en) 2004-03-04
WO2003000118A2 (en) 2003-01-03
CZ200487A3 (cs) 2004-10-13
US20040023925A1 (en) 2004-02-05
CA2451841A1 (en) 2003-01-03
IL159461A0 (en) 2004-06-01
CN1543351A (zh) 2004-11-03
JP2004535430A (ja) 2004-11-25
WO2003000118A3 (en) 2003-04-10
CN100558367C (zh) 2009-11-11
US20030013681A1 (en) 2003-01-16

Similar Documents

Publication Publication Date Title
BR0210550A (pt) Método para realçar a eficácia de terapias contra o câncer
BRPI0507451A (pt) método e terapia combinada para inibir o crescimento de tumor e/ou progressão metastática e/ou desenvolvimento de metástases, e, uso de uma imunoglobulina anti-alfa4 integrina
BR0213424A (pt) Uso aperfeiçoado de composto antitumoral na terapia contra câncer
BRPI0409919A (pt) combinações para o tratamento de doenças envolvendo proliferação, migração ou apoptose celular de células de células de mieloma, ou angiogênese
AR033157A1 (es) Uso de proteina alfa de activacion de los fibroblastos ("fapaalfa")bibh1 en el tratamiento del cancer
ES2172303T3 (es) Agentes terapeuticos obtenidos por catalisis enzimatica.
BR0112038A (pt) Triazolopirimidinas substituìdas como agentes anticâncer
EP1778352A4 (en) APPLICATOR FOR ADAPTIVE INTRACAVITARY CURIETHERAPY
ECSP055911A (es) Compuestos tricíclicos inhibidores de proteína quinasa para mejorar la eficacia de agentes antineoplásicos y terapia de radiación
UY27943A1 (es) Composiciones y mctodos para tratar el crncer usando inmunoconjugados de anticuerpo para cd44 citotnxicos y agentes quimioterapcuticos
EA200200616A1 (ru) Химические производные и их применение в качестве антителомеразного агента
CY1113600T1 (el) Θεραπειες συνδυασμου για λεμφωματα β-κυτταρου που περιλαμβανουν χορηγηση anti-cd20 αντισωματος
SV2004001291A (es) Alquinos como inhibidores de metaloproteinasa de matriz ref. pc20536
CR7575A (es) Uso de docetaxel/doxorrubicina/ciclofosfamida en la terapia adyuvante de cancer de mama y ovario
UY25992A1 (es) Procedimiento para preparar inhibidores de tace (enzima conversora del factor alfa de necrosis tumoral)
BRPI0417158A (pt) composto, composição farmacêutica, uso de um composto, método para prevenir, tratar ou melhorar uma doença ou condição associada com angiogênese desregulada, e, métodos para tratar ou melhorar cáncer, para reduzir o potencial metastático de um tumor, e para tratar ou melhorar tumores, e uma condição ou doença
BR9811948A (pt) Secretores de hormÈnio do crescimento
EA200300544A1 (ru) Эффективные противоопухолевые лекарственные средства
CY1110329T1 (el) Πεγκυλιωμενη λιποσωμιακη δοξορουβικινη σε συνδυασμο με εκτεϊνασκιδινη 743
ES2185323T3 (es) Utilizacion de eritropoietina en el tratamiento del mieloma multiple.
BRPI0517006A (pt) agente citotóxico, método para a sìntese de lipossomas incluindo uma solução, composição farmacêutica, método para o tratamento de uma doença hiperplásica ou neoplásica, uso de um agente citotóxico, e, kit para a formação de um agente citotóxico
DK1689404T3 (da) Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer
MX2022002312A (es) Composicion farmaceutica para tratar cancer utilizada para un paciente que tiene un marcador genetico especifico.
BR0208695A (pt) Composições e métodos para a prevenção e tratamento de c ncer humano da próstata
ATE290388T1 (de) Kombination von selen-haltigen verbindungen mit gemcitabin oder mitomycin c

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2029 DE 24/11/2009.